2017 American Transplant Congress » Poster Session A: Antibody Mediated Rejection in Kidney Transplant Recipients I

Date: Saturday, April 29, 2017

Time: 5:30pm-7:30pm

Location: Hall D1

Session Type: Poster Session

Meeting: 2017 American Transplant Congress

5:30pm-7:30pm: A Novel Computational HLA Matching Algorithm for Improving Donor-Recipient Histocompatibility and Graft Outcomes After Kidney Transplantation.

V. Kosmoliaptsis,¹ D. Mallon,¹ S. Fuggle,² R. Johnson,² C. Watson,¹ J. Bradley,¹ C. Taylor.¹

5:30pm-7:30pm: Activated Th1 and Th17 cT_FH Phenotype Correlates with DSA Production in Kidney Transplant Recipients.

C. Macedo, P. Fadakar, K. Hadi, B. Ellinof, A. Zeevi, S. Hariharan, D. Metes.

5:30pm-7:30pm: Antibody-Mediated Vascular Rejection of Kidney Allografts: What Does It Happen After 15 Years?

B. Rodriguez Cubillo,¹ I. Perez Flores,¹ M. Moreno De La Higuera,¹ M. Calvo,¹ N. Calvo Romero,¹ A. Pascual,² J. Cortes,² J. Blanco,² A. Sanchez-Fructuoso.¹

5:30pm-7:30pm: Banff 2013 Classification of Renal Allograft Pathology Is Superior to Banff 2007 in Detecting and Managing Milder and Earlier Cases of Antibody-Mediated Rejection.

J. Hassler,¹ V. Ariyamuthu,² A. Hendricks,¹ B. Tanriover,² J. Torrealba.¹

5:30pm-7:30pm: Blood Transfusion Before Organ Transplant: Patient Sensitization and Outcomes.

I. Cich, K. Rudser, R. Brown, H. Ibrahim, R. Thorson, J. Patil, G. Loor, M. Hertz, C. Cohn.

5:30pm-7:30pm: C3d-Binding Anti-DQ DSA Is Associated with a High Risk for Late ABMR and Graft Failure in Stable Kidney Transplant Recipients.

D. Lee,¹ B. Kim,² J. Kim,³ I. Kim,⁴ M. Chun.⁵

5:30pm-7:30pm: Can Pre-Treatment CDC Titres Predict Graft Outcomes in HLA Incompatible Transplants?

A. Prasad,¹ A. Yuvaraj,¹ D. Briggs,² N. Krishnan.¹

5:30pm-7:30pm: Chronic Antibody Mediated Rejection (cABMR) in ABO-Incompatible and ABO-Compatible Kidney Transplants: A Single US Center Experience.

S. Sethi, A. Vo, E. Huang, L. Varanasi, J. Choi, A. Peng, R. Najjar, S. Jordan.

5:30pm-7:30pm: Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.

S. Luque,² M. Lúcia,⁴ M. Jarque,² E. Crespo,² E. Melilli,¹ J. Martorell,³ J. Cruzado,^1,2 J. Torras,^1,2 J. Grinyó,^1,2 O. Bestard.^1,2

5:30pm-7:30pm: Comparison Between IgG, C1q and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.

M. Moreno Gonzales,¹ D. Mitema,² B. Smith,³ C. Schinstock,³ M. Stegall,³ M. Gandhi.³

5:30pm-7:30pm: Complement Binding Activity (C3d, C1q) of De Novo Donor-Specific HLA Antibody Is Associated with Increased Risk of Antibody-Mediated Rejection in Non-Sensitized Kidney Transplant Recipients.

H. Lee,¹ E. Han,¹ A.-R. Choi,¹ K. Park,² J. Ryu,² B. Chung,³ C. Yang,³ E.-J. Oh.¹

5:30pm-7:30pm: DSA Presence Does Not Affect Renal Histology and Clinical Outcome in Chronic Active Antibody Mediated Rejection.

K. Sablik,¹ M. Clahsen–van Groningen,¹ C. Looman,¹ J. Damman,¹ D. Roelen,² M. van Agteren,¹ M. Betjes.¹

5:30pm-7:30pm: Development of De Novo Donor Specific Antibodies (dnDSAs) Not the Presence of Pre-Transplant Donor Specific Antibodies (Pre-DSAs) Increase Rejection Risk in Crossmatch Negative Kidney Transplant Recipients.

H. Khamash, L. Archambault, M. Buras, H. Kosiorek, M. Pando, K. Reddy, B. Kaplan, R. Heilman.

5:30pm-7:30pm: Early Antibody-Mediated Rejection C4d Status Remains a Marker of Prognosis in HLA-Incompatible Kidney Transplantation.

J. Malheiro,¹ S. Santos,¹ S. Tafulo,² L. Dias,¹ L. Martins,¹ J. Ramon,¹ A. Castro-Henriques.¹

5:30pm-7:30pm: Elevated Circulating AT1R Levels Indicate Heightened Risk for Antibody Mediated Rejection and Graft Failure.

P. Kimball, G. Gupta, F. McDougan.

5:30pm-7:30pm: Gene Expression Signature of Subclinical Allograft Kidney ABMR Compared to Clinical ABMR.

O. Aubert,¹ C. Lefaucheur,¹ S. Higgins,¹ L. Hidalgo,² J. Duong Van Huyen,¹ D. Viglietti,¹ X. Jouven,¹ D. Glotz,¹ C. Legendre,¹ P. Halloran,² A. Loupy.¹

5:30pm-7:30pm: Graft Immunocomplex Capture Fluorescence Analysis to Detect Donor Specific Antibodies and HLA Antigen Complexes in the Renal Allograft.

T. Nakamura,¹ H. Ushigome,¹ K. Watabe,² Y. Imanishi,² S. Harada,¹ S. Nobori,¹ K. Masuda,¹ N. Yoshimura.¹

5:30pm-7:30pm: HLA Donor-Specific Antibody (DSA) Negative Antibody-Mediated Rejection (AMR): Incidence, Treatment and Outcomes.

R. Redfield, S. Parajuli, W. Zhong, B. Astor, A. Djamali, D. Mandelbrot.

5:30pm-7:30pm: IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-CMV IgG, Resulting in Inhibition of Antibody (Ab)-Mediated NK Cell Activation in Kidney Transplant Patients (KTX Pts).

B.-H. Shin,¹ S. Ge,¹ M. Chu,¹ J. Choi,¹ L. Winstedt,² C. Kjellman,² S. Louie,¹ A. Vo,¹ A. Peng,¹ S. Jordan,¹ M. Toyoda.¹

5:30pm-7:30pm: Identification of Antibody-Mediated Rejection After Kidney Transplantation by Specific MicroRNAs.

M. Matz,¹ F. Heinrich,² P. Durek,² C. Lorkowski,¹ K. Wu,³ N. Lachmann,⁴ K. Budde,¹ M.-F. Mashreghi.²

5:30pm-7:30pm: Microarray Analysis of Rejection in Formalin-Fixed Paraffin-Embedded Biopsies: Similarities and Disparities with Conventionally Stabilized Biopsies.

K. Famulski, J. Revee, P. Halloran.

5:30pm-7:30pm: Microcirculation Inflammation in Kidney Allograft Biopsies.

M. Giordani,¹ M. Bedini Rocca,¹ S. Groppa,¹ C. Mombelli,¹ S. Christiansen,² M. Ocampo,¹ G. Rosa Diez,¹ N. Imperiali.¹

5:30pm-7:30pm: Mycophenolate Dose Reductions Are Not Associated with De Novo Donor-Specific Antibodies.

S. Davis, J. Gralla, P. Klem, A. Wiseman, J. Cooper.

5:30pm-7:30pm: Poor Prediction of Rejection and Kidney Survival by Donor-Specific-Antibodies Characterization.

L. Couzi,^1,2,3 M. Courant,¹ J. Visentin,^1,2,3 V. Dubois,⁴ S. Lepreux,^1,2 G. Guidicelli,¹ O. Thaunat,^5,6 P. Merville,^1,2,3 J.-L. Taupin.⁷

5:30pm-7:30pm: Regulatory T Cells Inhibit Plasmablast Formation and IgG Production by Tempering T Follicular Helper Cell Function.

P. Fadakar, C. Macedo, M. Yamada, K. Hadi, D. Metes.

5:30pm-7:30pm: Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens.

B. Javaid, S. Rosen-Bronson, D. Li, M. Awwad, A. Gilbert, S. Ghasemian, J. Verbesey, P. Abrams, M. Grafals, J. Fenton, C. Cannon, J. Rapisura, J. Moore, M. Cooper.

5:30pm-7:30pm: Risk Factors of Treatment Failure in Antibody Mediated Rejection.

V. Pernin,¹ I. Szwarc,¹ T. Kanouni,² V. Garrigue,¹ J. Serre,¹ S. Delmas,¹ G. Mourad,¹ M. Le Quintrec.¹

5:30pm-7:30pm: Single Nuclear Polymorphisms of Complement Component 4 and Component 5 in Renal Transplant Recipients with Antibody-Mediated Rejection.

Z. Wang, Z. Han, J. Tao, R. Tan, M. Gu.

5:30pm-7:30pm: Steroid Withdrawal and De Novo Donor-Specific HLA Antibodies in Renal Transplant Patients: A Prospective, Randomized, Controlled Study in Parallel Groups. Preliminary Results.

J. Alonso-Titos,¹ P. Ruiz-Esteban,¹ E. Palma,¹ V. Lopez,¹ A. Caballero,² M. Leon,³ M. Cobos,⁴ J. Cruzado,⁵ J. Sellares,⁶ A. Torres,⁴ D. Hernandez.¹

5:30pm-7:30pm: Urinary Proteomic Biomarkers Discovery for Prediction of Acute Rejection in Kidney Transplant Recipients.

H.-Y. Jung, R. Kim, S. Park, J. Park, K. Lee, E. Lee, J.-H. Lim, K. Kim, J.-Y. Choi, J.-H. Cho, S.-H. Park, Y.-L. Kim, C.-D. Kim.

« View all sessions from the 2017 American Transplant Congress